Hitting the Mark - Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer.
0/5 보강
APA
Rugo HS (2026). Hitting the Mark - Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer.. The New England journal of medicine, 394(9), 918-920. https://doi.org/10.1056/NEJMe2600247
MLA
Rugo HS. "Hitting the Mark - Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer.." The New England journal of medicine, vol. 394, no. 9, 2026, pp. 918-920.
PMID
41740036 ↗
같은 제1저자의 인용 많은 논문 (5)
- Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice.
- OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.
- Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.
- KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy.
- Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.